Viropro Inc. (OTCPK: VPRO)

About Viropro Inc.

Viropro Inc., a subsidiary of Alpha Biologics Limited, functions as a contract research and manufacturing organization (CRMO), primarily engaged in the development and production of biotherapeutic proteins aimed at treating diverse medical conditions. The company additionally facilitates the industrial-scale manufacturing of biogeneric therapeutic proteins through the licensing of its proprietary technologies, targeting illnesses like cancer, diabetes, hepatitis, and multiple sclerosis. Viropro manufactures a range of biologics drugs, including biosimilars, for use across all phases of clinical development, from pre-clinical studies through Phase I, II, and III trials. Its offerings to clients include the provision of mammalian cell proteins, such as monoclonal antibodies, recombinant proteins, and other cell-derived compounds. Notably, the firm owns three proprietary clones: two intended for insulin-related therapies and one for cancer treatment. Viropro delivers extensive contractual research and manufacturing solutions to biotech and biopharmaceutical enterprises, performing tasks such as cloning, sequencing, purification, development, validation, and production of biopharmaceutical components and finished products. The company maintains operational presences in Canada, the United Kingdom, and Malaysia, and has established a partnership with Oncobiologics, Inc. for the creation and commercialization of monoclonal antibody products. Viropro Inc. is headquartered in San Jose, California.

ISIN

US9282422057

Listed since

Apr 20, 1995

Exchange

Pink Sheets LLC

Currency

USD